Ann: Licencing Deal Expands Noxopharm Drug Opportunities, page-6

A major newspaper noted yesterday that a Class Action involving at least 10,000 claimants intended to sue the Government over side effects from COVID vaccines, principally myocarditis and pericarditis. These are the very side effects that the HIMR technology is designed to stop.

At the same time, the HIMR technology is expected to improve manufacturing efficiency by 20% - 40%.

I imagine that this technology will be immediately offered to EVERY mRNA manufacturer on a non-exclusive basis. They could decline, of course, but would know that their vaccine could be significantly inferior to any competitor vaccine that utilises a Pharmorage Licence.

This is a fantastic development for Noxopharm, which stands to earn up-front Licence fees, plus on-going royalties.